

GENETIC SIGNATURES SIGNS DANISH SUPPLY AGREEMENT

Sydney, Australia, Genetic Signatures Limited (ASX: GSS) ("Genetic Signatures" or "the Company") is pleased to advise it has signed agreements for the supply of Equipment, Reagents and Consumables for Gastrointestinal Screening at Hvidovre Hospital in Denmark. The Reagent and Consumables Supply Agreement has a ten-year term, extendable for up to two 12-month periods. The Equipment Supply Agreement has no fixed term, which is customary in supply agreements of this nature, but are generally expected to run eight years or longer.

Hvidovre is one of Denmark's leading public hospitals and the contract is for the testing of 28,000 samples in the first year, with a 3% estimated growth annually. The pricing of the tests is commercially sensitive and will not be released publicly. A customary installation and validation process will commence immediately with commercial orders expected from September 2026.

Under the agreement, Hvidovre Hospital will adopt Genetic Signatures' *EasyScreen*[™] Pan-Enteric assay, based on its proprietary 3base® multiplex technology, which detects a broad range of strains of 24 gastrointestinal pathogens in a single, fully automated workflow. Secured following a competitive tender process, the contract reflects growing international recognition of the clinical and operational advantages of the Company's pan-enteric diagnostic approach.

Genetic Signatures' pan-enteric approach consolidates what has traditionally required complex multi-test algorithms, including culturing, ELISA, and multiple PCR tests, into a streamlined workflow. This simplification delivers material benefits across the laboratory and broader hospital environment, including reduced risk through the elimination of multi-platform complexity. The resultant improvement in infection-control reduces unnecessary admissions, prevents ward closures and shortens patient stay.

The clinical and operational value of this approach has previously been validated in the United Kingdom in hospital environments following adoption of the *EasyScreen*[™] Pan-Enteric assay. Key outcomes of these studies included:

- Reduction in ward closures following implementation
- Tripling of diagnostic yield and improved detection of clinically important pathogens
- Reduction of turnaround times and simplified laboratory workflows
- Reduction in staffing requirements and increased walk-away time
- Rapid results that directly informed admission decisions, bed management, targeted antibiotic use, and infection-control actions
- A marked decline in *Clostridioides difficile* infections

These outcomes highlight the broader, system-wide health economic value of the *EasyScreen*[™] Pan-Enteric assay from the laboratory bench through to patient management and hospital operations.

"The Hvidovre Hospital tender is a critical milestone for Genetic Signatures' EMEA growth strategy and further validates the clinical and operational case for our *EasyScreen*[™] Pan-Enteric solution in international markets. Denmark has a sophisticated and demanding healthcare system, and we are proud that our technology meets the gastrointestinal diagnostic needs of Hvidovre Hospital" said Director of EMEA Operations, John Buckles.

"This contract, combined with the outcomes we have seen in the UK and other markets, demonstrates that our pan-enteric approach delivers measurable, real-world benefits for laboratories, clinicians, and ultimately patients. We see this as a strong signal of growing momentum for broader adoption of our platform across Europe and globally" added CEO of Genetic Signatures, Maria Halasz.

About the *EasyScreen*™ Pan-Enteric Assay

The *EasyScreen*™ Pan-Enteric assay, powered by Genetic Signatures' patented 3base® technology, enables simultaneous detection of 24 gastrointestinal pathogens, including bacteria, viruses, and parasites, from a single patient sample in one automated run. The assay is designed for high-throughput clinical laboratories seeking to improve diagnostic accuracy, reduce complexity, and deliver faster, more comprehensive and clinically actionable results to support better patient outcomes.

About Genetic Signatures Limited

Genetic Signatures Limited (ASX: GSS) is an Australian molecular diagnostics company focused on the development and commercialisation of molecular detection products for infectious diseases. The Company's proprietary 3base® technology platform simplifies the detection of pathogens, offering superior sensitivity and specificity across a broad range of clinical applications. Genetic Signatures markets its *EasyScreen*™ range of diagnostic assays globally, with a growing commercial presence across Europe, the United Kingdom, and the Asia-Pacific region.

Authorised for release by the Board of Genetic Signatures Limited

For further information, see our website (www.geneticsignatures.com) or contact us:

Daniel Ireland

Investor Relations

Daniel.ireland@datair.com.au

0428 607 884